UPDATE: RBC Capital Downgrades Metacrine Inc. (MTCR) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Canaccord Genuity Downgrades Metacrine Inc. (MTCR) to Hold
October 22, 2021 4:24 AM EDTCanaccord Genuity analyst Edward Nash downgraded Metacrine Inc. (NASDAQ: MTCR) from Buy to Hold with a price target of $1.00 (from $19.00).
For an analyst ratings summary and ratings history on Metacrine Inc. click here. For more ratings news on Metacrine Inc. click here.
Shares of Metacrine Inc. closed at $3.83 yesterday.
... MoreMetacrine (MTCR) Announces Interim Results for MET642 Phase 2a Trial in Patients with NASH; Announces Strategic Re-Prioritization of Its Clinical Development Programs
October 21, 2021 4:01 PM EDTMetacrine, Inc. (NASDAQ: MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis (NASH) patients after 16 weeks of treatment. The Company also announced it is prioritizing its clinical development effort and resources to advance MET642 into a Phase 2 trial in inflammatory bowel disease (IBD) in the first half of 2022.
The Phase 2a trial... More
